ARD:针对 1 型血管紧张素受体的诱导抗体会引发跨物种的皮肤和肺部炎症以及真皮纤维化

2022-05-28 MedSci原创 MedSci原创

该研究的免疫策略诱导了血管紧张素受体1型(AT1R)自身抗体 (Abs),通过激活AT1R促进炎症,并可能导致纤维化。因此,AT1R Abs是未来治疗SSc和其他AT1R Ab相关疾病的有价值的靶点。

目的:血管紧张素受体1 (AT1R, AGTR1) 是一种G蛋白偶联受体(GPCR),主要参与调节血管张力、血管平滑肌细胞增殖、细胞外基质生成和炎症。这项研究目的在于确定针对AT1R的自身抗体 (Abs) 的贡献和功能,这些抗体被认为与AT1R Abs相关疾病如系统性硬化症(SSc)的发病机制有关。

方法:用膜包埋的人AT1R或空膜作为对照对C57BL/6J小鼠进行免疫。CD4+CD8+ T 细胞和B细胞缺陷的小鼠用膜包埋的AT1R或被认为是主要T细胞表位的AT1R肽进行免疫。通过杂交瘤技术产生单克隆(m)AT1R Ab并转移到C57BL/6JAT1Ra/b敲除小鼠中。通过组织学、免疫组织化学、免疫荧光、细胞凋亡测定和ELISA检查诱导的表型。在体外,在不同来源和物种的细胞中测量了对AT1RAbs反应。

结果:AT1R免疫小鼠出现血管周围皮肤和肺部炎症、淋巴细胞性肺泡炎、弱肺内皮细胞凋亡和伴有Smad2/3信号传导的皮肤纤维化,在对照或缺乏CD4+ TB细胞的小鼠中不存在以上病理现象。AT1R149-172引起肺部炎症。mAT1R Ab的应用诱导皮肤和肺部炎症,在 AT1Ra/b敲除小鼠中未观察到。在体外,AT1R Abs激活大鼠心肌细胞和人单核细胞,通过AT1R结合增强AT1R转染的HEK293细胞中血管紧张素II介导的AT1R激活,并且mAT1R Ab激活的单核细胞介导真皮成纤维细胞中促纤维化标志物的诱导。

结论:该研究的免疫策略成功地诱导了AT1R Abs,通过激活AT1R促进炎症,并可能导致纤维化。因此,AT1R Abs是未来治疗SSc和其他AT1R Ab相关疾病的有价值的靶点。

 

出处:

Yue X, Yin J, Wang X, et al. Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching. Annals of the Rheumatic Diseases Published Online First: 20 May 2022. doi: 10.1136/annrheumdis-2021-222088

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046775, encodeId=73952046e75f9, content=<a href='/topic/show?id=ed2193101cb' target=_blank style='color:#2F92EE;'>#跨物种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93101, encryptionId=ed2193101cb, topicName=跨物种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 26 16:01:20 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940605, encodeId=5aab19406056f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Mon Jan 02 03:01:20 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589370, encodeId=72f015893e000, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sun May 29 12:01:20 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222995, encodeId=4d451222995e7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a178183980, createdName=ms1000000770849501, createdTime=Sat May 28 15:05:03 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-12-26 respect
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046775, encodeId=73952046e75f9, content=<a href='/topic/show?id=ed2193101cb' target=_blank style='color:#2F92EE;'>#跨物种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93101, encryptionId=ed2193101cb, topicName=跨物种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 26 16:01:20 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940605, encodeId=5aab19406056f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Mon Jan 02 03:01:20 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589370, encodeId=72f015893e000, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sun May 29 12:01:20 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222995, encodeId=4d451222995e7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a178183980, createdName=ms1000000770849501, createdTime=Sat May 28 15:05:03 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046775, encodeId=73952046e75f9, content=<a href='/topic/show?id=ed2193101cb' target=_blank style='color:#2F92EE;'>#跨物种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93101, encryptionId=ed2193101cb, topicName=跨物种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 26 16:01:20 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940605, encodeId=5aab19406056f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Mon Jan 02 03:01:20 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589370, encodeId=72f015893e000, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sun May 29 12:01:20 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222995, encodeId=4d451222995e7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a178183980, createdName=ms1000000770849501, createdTime=Sat May 28 15:05:03 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046775, encodeId=73952046e75f9, content=<a href='/topic/show?id=ed2193101cb' target=_blank style='color:#2F92EE;'>#跨物种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93101, encryptionId=ed2193101cb, topicName=跨物种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 26 16:01:20 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940605, encodeId=5aab19406056f, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Mon Jan 02 03:01:20 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589370, encodeId=72f015893e000, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sun May 29 12:01:20 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222995, encodeId=4d451222995e7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a178183980, createdName=ms1000000770849501, createdTime=Sat May 28 15:05:03 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-05-28 ms1000000770849501

    很好

    0

相关威廉亚洲官网

A&R:系统性硬化症的舒张功能障碍:危险因素和对死亡率的影响

舒张功能障碍与系统性硬化症(SSc)患者死亡风险增加独立相关。应在SSc患者中解决潜在可改变的风险因素,包括冠状动脉疾病和肥胖以降低死亡风险。

ARD:对系统性硬化症中纵向皮肤基因表达的大规模分析

系统性硬化症 (SSc) 患者皮肤厚度与免疫细胞和成纤维细胞基因表达失调有关。在早期弥漫性SSc 中,皮肤基因表达随时间而变化,并趋于正常化。

Lancet Rheumatolgoy:异体骨髓来源的多能间充质基质细胞治疗系统性硬化症的安全性和初步疗效

在患有严重弥漫性系统性硬化症的患者中,单次输注异体骨髓来源的间充质基质细胞是安全的。

Stem Cell Res Ther:间充质干细胞或是治疗系统性硬化症的有效疗法

系统性硬化症(SSc)是一种发病率和死亡率都很高的自身免疫性疾病,其特点是皮肤和内部器官的纤维化。有研究显示,使用干细胞可有效治疗SSc。

A&R:受损的线粒体转录因子A表达促进线粒体损伤以驱动系统性硬化症中的成纤维细胞活化和纤维化

关键的线粒体转录因子A (TFAM)响应转化生长因子β(TGFβ)的延长激活和相关的线粒体损伤而发生的改变会诱导促进成纤维细胞向肌成纤维细胞转化的转录程序。

A&R:细胞周期蛋白依赖性激酶4/6抑制剂对系统性硬化小鼠模型皮肤纤维化的治疗作用

真皮纤维化的小鼠模型中,用CDK4/6抑制剂治疗小鼠可降低真皮厚度和胶原蛋白含量,以及真皮成纤维细胞增殖和肌成纤维细胞数量。 CDK4/6抑制剂和TGFβR抑制剂的联合治疗产生了附加的抗纤维化作用。